TR201810389T4 - Polimerik finasterid ve minoksidil nanopartikülleri, bunları hazırlamak için yöntem, bunları içeren aköz süspansiyon, farmasötik bileşim ve bunların kullanımı. - Google Patents

Polimerik finasterid ve minoksidil nanopartikülleri, bunları hazırlamak için yöntem, bunları içeren aköz süspansiyon, farmasötik bileşim ve bunların kullanımı. Download PDF

Info

Publication number
TR201810389T4
TR201810389T4 TR2018/10389T TR201810389T TR201810389T4 TR 201810389 T4 TR201810389 T4 TR 201810389T4 TR 2018/10389 T TR2018/10389 T TR 2018/10389T TR 201810389 T TR201810389 T TR 201810389T TR 201810389 T4 TR201810389 T4 TR 201810389T4
Authority
TR
Turkey
Prior art keywords
finasteride
minoxidil
pharmaceutical composition
alopecia
constituting
Prior art date
Application number
TR2018/10389T
Other languages
English (en)
Inventor
Raffin Pohlmann Adriana
Soledade Jornada Denise
Pinheiro Do Nascimento Ludmila
Stanisçuaski Guterres Silvia
Original Assignee
Biolab Sanus Farmaceutica Ltda
Univ Federal Do Rio Grande Do Sul Ufrgs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50182296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201810389(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmaceutica Ltda, Univ Federal Do Rio Grande Do Sul Ufrgs filed Critical Biolab Sanus Farmaceutica Ltda
Publication of TR201810389T4 publication Critical patent/TR201810389T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Bu buluş, finasterid ve minoksidil adlı iki etkin bileşenin yer aldığı polimerik nanopartiküller, tercihen nanokapsüller ve ayrıca katkı maddeleri ve bir farmasötik açıdan kabul edilebilir taşıyıcı ihtiva eden ve alopesinin tedavisinde kullanıma yönelik olan topikal uygulamalı bir farmasötik bileşim ile ilgilidir. Bu buluş, ayrıca, alopesinin tedavisi için uygun topikal uygulamalı bir bileşimi teşkil eden finasterid ve minoksidilin yer aldıkları polimerik nanopartikülleri, tercihen nanokapsülleri hazırlamaya yönelik bir hazırlama prosesi ve ayrıca bahsi geçen nanokapsüllerin bir farmasötik bileşim hazırlamak için kullanımı ile de ilgilidir.

Description

Tarifname içerisinde atifta bulunulan patent dökümanlari: Tarifnamede belirtilen patentlestirilmemis literatür: - DRAKE, L. et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology, ° INUI, S. ; ITAMI, S. Molecular basis androgen to paracrine mediators through derinal papilla. Journal of Dermatological Science, 201 1, vol. 61, 1-6 [0004] ° TRUEB, RM. Molecular mechanisms of androgenetic alopecia. Experimental 990 [0004] o LIU, S.; YAMAUCHI, H. Different patterns of Su-reductase expression, cellular distribution, and testosterone inetabolism in human follicular derinal Biophysical Research Cominunications, o INUI, S . ; ITAMI, S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators - SCHAFFAZICK, SH et al.
Characterization and physicochemical stability of nanoparticle polymeric formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics, 1989, vol. 55 (1), R1-R4 [0011] the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects. Bioorganic & Medicinal Chemistry Letters, 2007, vol.
° LADEMANN, J. et al. Nanoparticles - An efficient carrier for drug delivery into the hair follicles. European Journal of Pharmaceutics and Biophaririaceutics, 2007, vol. 66 (2), ° SINCLAIR, RD. Male androgenetic through dermal papilla. Journal of Derinatological Science, 2011, vol. 61, 1-6 [0005] o ELLIS, JA ; HARRAP, SB. The genetics of androgenetic alopecia.
Clinics in Dermatology, 2001 , vol. alopecia. The Journal of Men's Health o AVNESH KUMARI ; SUDESH KUMAR YADAV ; SUBHASH C. nanoparticle based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 01 January ° VLADIMIR P. TORCHILIN.
RECENT ADVANCES WITH LIPOSOMES AS HARMACEUTICAL CARRIERS. NATURE REVIEW S, alopecia: Part 11. The Journal of Men°s Health & Gender, 2005, vol. 2 (1), 38-44 [0029] - STOUT, SM; STUMPF, JL.
Finasteride Treatment of Hair Loss in Women. The Annals of Pharmacotherapy, contact dermatitis to topical minoxidil solution: Etiology and treatment.
Journal of the American Academy of 312 [0030] o MATIAS, JR et al. Animal models of androgen-dependent disorders of the piloscbaceous apparatus. 1. The androchronogenetic alopecia (AGA) Mouse as a model for male-pattern baldness. Archives of Dermatological SEKILLERDEKI YAZILARIN ANLAMLARI A = Grafik B : Hacim C = Partikül Büyüklügü D = Alan basina hücre sayisi 10000 10000 40.00

Claims (6)

  1. ISTEMLER 1.
  2. Finasterid ve minoksidil etkin bilesenlerini ihtiva eden ve asagida belirtilen unsurlar ile elde edilebilecek olan bir nanokapsoid formundaki polimerik nanopartikül: (i) asagida belirtilenleri içeren bir organik faz: (a) erime noktasi IZOOC'den düsük olan polyesterler grubu arasindan seçilen bir biyobozunur polimeri teskil eden bir hidrofobik polimer, bir poli(g- kaprolakton); (b) orta boy ziiicirli trigliseritler arasindan seçilen bir sabit yag; (0) 3 ile 6 arasi bir degere tekabül eden düsük bir HLB'nin söz konusu oldugu bir lipofilik yüzey aktif madde, bir sorbitan monostearat; (d) asetonu teskil eden bir organik çözücü, (e) etanolü teskil eden bir es-çözü.cü;ve (Ü finasterid; ve (ii) asagida belirtilenleri içeren bir aköz faz: (g) polisorbat 80'i teskil eden bir hidrofilik yüzey aktif madde; (h) minoksidil; ve Istein l'e uygun poliinerik nanopartik'ul olup, burada bahsi geçen orta boy Zincirli trigliseritler, kaprilik ve kaprik asit trigliseritleridir.
  3. Istem l'e uygun polimerik nanopartikûl olup, burada (i) bahsi geçen organik faz asagida belirtilenleri içerir: (21) %0,05 ile %20,0 (a/a) arasi bir oranda bir poli(8-kaprolakton); (b) %0,05 ile %25,0 (a/a) arasi bir oranda orta boy Zincirli trigliseritler; (0) %0,05 ile %25,0 (a/a) arasi bir oranda bir sorbitan monostearat; (d) %10 ile %80 (a/a) arasi bir oranda aseton; (e) %0,001 ile %50 (a/a) arasi bir oranda etanol; ve (f) %0,005 ile %50,0 (a/a) arasi bir oranda finasterid; ve (ii) bahsi geçen ak'oz faz asagida belirtilenleri içerir: (g) %0,005 ile %50,0 (a/a) arasi bir oranda ininoksidil; (h) %0,05 ile %20,0 (a/a) arasi bir oranda polisorbat 80; ve (i) %10 ile %90 (a/a) arasi bir oranda su.
  4. 4. Asagida belirtilenleri içeren ve alopesinin tedavisinde kullaniin için olan farmasötik bilesim: (A) istemler 1 ilâ 3'e uygun, bir nanokapsoid formunda bulunan, %0,01 ile %1,0 (a/a) arasi bir oranda finasterid ve %0,01 ile %2,0 (a/a) arasi bir oranda minoksidil; ve (B) bir farmasötik açidan kabul edilebilir tasiyici.
  5. 5. Topikal uygulama için olan ve bir çözelti, jel veya losyon formunda bulunan, istem 4'e uygun kullanim için, farmasötik bilesim.
  6. 6. Alopesinin tedavisinde kullanim için, istemler l ilâ 3'ten herhangi birinde tanimlandigi gibi olan nanokapsoidler formundaki polimerik nanopartikül.
TR2018/10389T 2012-08-31 2013-08-30 Polimerik finasterid ve minoksidil nanopartikülleri, bunları hazırlamak için yöntem, bunları içeren aköz süspansiyon, farmasötik bileşim ve bunların kullanımı. TR201810389T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012022036-9A BR102012022036B1 (pt) 2012-08-31 2012-08-31 Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso

Publications (1)

Publication Number Publication Date
TR201810389T4 true TR201810389T4 (tr) 2018-08-27

Family

ID=50182296

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/10389T TR201810389T4 (tr) 2012-08-31 2013-08-30 Polimerik finasterid ve minoksidil nanopartikülleri, bunları hazırlamak için yöntem, bunları içeren aköz süspansiyon, farmasötik bileşim ve bunların kullanımı.

Country Status (23)

Country Link
US (1) US9687554B2 (tr)
EP (1) EP2891486B1 (tr)
JP (1) JP6352265B2 (tr)
KR (1) KR102118582B1 (tr)
CN (1) CN104755075B (tr)
AR (1) AR092403A1 (tr)
AU (1) AU2013308356B2 (tr)
BR (1) BR102012022036B1 (tr)
CA (1) CA2883998C (tr)
CL (1) CL2015000501A1 (tr)
CO (1) CO7310520A2 (tr)
DK (1) DK2891486T3 (tr)
ES (1) ES2683418T3 (tr)
IN (1) IN2015DN01728A (tr)
MX (1) MX363961B (tr)
MY (1) MY174692A (tr)
PE (2) PE20150732A1 (tr)
SA (1) SA515360084B1 (tr)
TR (1) TR201810389T4 (tr)
UA (1) UA113774C2 (tr)
UY (1) UY35002A (tr)
WO (1) WO2014032152A1 (tr)
ZA (1) ZA201501255B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174254A1 (en) * 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US9675537B2 (en) * 2014-06-30 2017-06-13 Johnson & Johnson Consumer Inc. Hair growth composition and method
CN104887685A (zh) * 2015-05-05 2015-09-09 谢秉权 一种治疗和/或预防男性型脱发的复方外用药
ES2613888B1 (es) * 2016-08-19 2017-11-16 Enrique Blanxart Sena Composición farmacéutica para el tratamiento de la alopecia
WO2018206077A1 (en) * 2017-05-08 2018-11-15 Merz Pharma Gmbh & Co. Kgaa Emulsion comprising finasteride
DK3638198T3 (da) * 2017-06-16 2021-11-22 Capilli Med Gmbh Sammensætning til at forebygge hårtab og fremme hårvækst
MX2018001546A (es) * 2018-02-06 2019-08-07 Centro Int De Cosmiatria S A P I De C V Formulacion y metodo para el tratamiento de la alopecia androgenica.
CN110448525A (zh) * 2018-05-08 2019-11-15 无锡派列博生物医药科技有限公司 一种预防脱发和促生发的外用非那雄胺脂质纳米制剂及其制备方法
WO2020097284A1 (en) * 2018-11-08 2020-05-14 Jindal Vinay K TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF
WO2020121329A1 (en) * 2018-12-11 2020-06-18 Dr Rathod Sudha Suresh Minoxidil and castor oil nanoemulgel for alopecia
CN112773776B (zh) * 2019-11-11 2023-06-20 上海胜联医药科技有限公司 一种载药纳米粒体系
CN111329832B (zh) * 2020-02-08 2021-07-16 中山大学 一种治疗脱发的纳米脂质载体微针及其应用
EP4114362A4 (en) * 2020-03-05 2024-03-20 Univ Miami NANODRUG FORMULATIONS OF CANNABIDIOL AND THEIR METHODS OF USE
AU2020389480A1 (en) 2020-03-30 2021-10-14 Hyundaibioscience Co.,Ltd. Ethosomal composition including ethosomes encapsulating vitamin and dexpanthenol and method for preparing the same
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
CN114910567B (zh) * 2021-02-07 2023-11-24 株洲千金药业股份有限公司 一种检测非那雄胺中遗传毒性杂质的方法及其应用
CN113425845B (zh) * 2021-08-10 2022-12-02 成都倍特药业股份有限公司 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途
CN113797208B (zh) * 2021-11-17 2022-02-25 山东谷雨春生物科技有限公司 一种含米诺地尔的制剂及其制备方法和应用
KR20230113871A (ko) 2022-01-24 2023-08-01 (주) 해피론이엔지 발포폴리에틸렌메시를 이용한 건축물 층간소음방지 시공방법 및 구조.
KR102623083B1 (ko) 2022-05-02 2024-01-10 (주) 해피론이엔지 공명공간을 제거한 1차 몰탈 타설식 소음방지 시공공법 및 시공구조
CN115006712B (zh) * 2022-06-28 2024-01-09 广州汇元医药科技有限公司 一种米诺地尔的脂质纳米粒微针及其制备方法和应用
CN115252549B (zh) * 2022-07-12 2023-09-08 科辉智药生物科技（无锡）有限公司 提高生发活性物质药效的组合物及其制备方法
CN115400085A (zh) * 2022-09-02 2022-11-29 南昌大学 一种非那雄胺类脂囊泡及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
EP1154783A4 (en) * 1999-07-06 2005-01-19 Raziel Lurie RELAXIN-CONTAINING MEDICAMENTS AND ITS USE
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
WO2005000258A1 (en) 2003-06-27 2005-01-06 Amorepacific Corporation Self-assembled polymeric nanoparticles containing physiologically active ingredients and external application containing the nanoparticles
JP4939936B2 (ja) * 2003-06-27 2012-05-30 株式會社アモーレパシフィック 生理活性成分を含有する自己集合性高分子ナノ粒子の製造方法、及び得られた自己集合性高分子ナノ粒子を含有する外用剤組成物
WO2006099121A2 (en) 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
CN101500937A (zh) * 2006-08-11 2009-08-05 万能药生物有限公司 用于递送活性成分的粒子及其制备方法和组合物
US20080175807A1 (en) 2007-01-24 2008-07-24 Fujifilm Corporation Composition for hair
BRPI0700832B8 (pt) * 2007-03-16 2021-05-25 Biolab Sanus Farmaceutica Ltda composição anestésica tópica compreendendo suspensão de nanocápsulas poliméricas de lidocaína e prilocaína
WO2009058135A1 (en) * 2007-10-30 2009-05-07 Celonova Biosciences, Inc. Loadable polymeric microparticles for therapeutic use in alopecia and methods of preparing and using the same
LT2344198T (lt) 2008-09-27 2021-02-25 Jina Pharmaceuticals Inc. Farmaciniai preparatai lipidų pagrindu, skirti vietiniam naudojimui
WO2011031990A1 (en) * 2009-09-11 2011-03-17 Follica, Inc. Intermittent and pulse lithium treatments for modulating hair growth
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos

Also Published As

Publication number Publication date
MX363961B (es) 2019-04-09
CA2883998C (en) 2020-08-25
CN104755075A (zh) 2015-07-01
MY174692A (en) 2020-05-07
KR20150044029A (ko) 2015-04-23
EP2891486A1 (en) 2015-07-08
BR102012022036A2 (pt) 2014-11-25
ES2683418T3 (es) 2018-09-26
AR092403A1 (es) 2015-04-22
CN104755075B (zh) 2019-07-26
IN2015DN01728A (tr) 2015-05-29
PE20150732A1 (es) 2015-05-17
US9687554B2 (en) 2017-06-27
JP2015526484A (ja) 2015-09-10
CO7310520A2 (es) 2015-06-30
US20150216986A1 (en) 2015-08-06
KR102118582B1 (ko) 2020-06-04
AU2013308356A1 (en) 2015-04-16
JP6352265B2 (ja) 2018-07-04
MX2015002300A (es) 2016-02-10
EP2891486B1 (en) 2018-05-16
UY35002A (es) 2014-03-31
EP2891486A4 (en) 2016-03-23
UA113774C2 (xx) 2017-03-10
CL2015000501A1 (es) 2015-07-03
WO2014032152A1 (pt) 2014-03-06
PE20191714A1 (es) 2019-12-05
CA2883998A1 (en) 2014-03-06
DK2891486T3 (en) 2018-07-23
BR102012022036B1 (pt) 2019-10-01
ZA201501255B (en) 2016-01-27
AU2013308356B2 (en) 2017-09-28
SA515360084B1 (ar) 2016-10-03

Similar Documents

Publication Publication Date Title
TR201810389T4 (tr) Polimerik finasterid ve minoksidil nanopartikülleri, bunları hazırlamak için yöntem, bunları içeren aköz süspansiyon, farmasötik bileşim ve bunların kullanımı.
KR102128478B1 (ko) 중합 피나스테리드 나노입자, 이를 포함한 수성 조성물, 탈모 치료를 위한 조성물 및 이의 제조 공정 및 이 조성물의 용도
ES2268856T3 (es) Composicion farmaceutica.
EP1870081B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
FR2812190A1 (fr) Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
Pereira-Silva et al. Nanomaterials in hair care and treatment
Kochar et al. Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia
RU2015108835A (ru) Полиоксиалкилен-замещённые алкилендиамины и их применение для кожи и волос
KR20050083836A (ko) 멜라토닌, 징코 빌로바, 및 비오틴을 포함하는 제제
Rancan et al. Hair follicle targeting with nanoparticles
KR101998103B1 (ko) 중간엽 줄기세포 유래 나노베지클을 포함한 탈모 방지 또는 발모 촉진용 조성물
FR2812192A1 (fr) Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
Pitaksuteepong et al. Targeted transfollicular delivery of artocarpin extract from Artocarpus incisus by means of microparticles
Zarkesh et al. Preparation and physicochemical characterization of topical niosomal formulation of minoxidil and tretinoin
JP2016522218A (ja) 二段階の封入構造を有するシクロデキストリンを備えた微粒子
CN104739807B (zh) 一种总蟾毒内酯纳米胶束制剂及其制备方法
KR20170100804A (ko) 안정화된 푸코잔틴의 나노리포좀 입자의 제조방법 및 동 방법에 의해 제조된 나노리포좀 입자를 함유하는 화장료조성물
Almutairy et al. Spanlastic-laden nanogel as a plausible platform for dermal delivery of bimatoprost with superior cutaneous deposition and hair regrowth efficiency in androgenic alopecia
JP2022547445A (ja) 活性剤を含む生体接着性粒子、及びその使用
KR20170134103A (ko) 알리솔 b 23-아세테이트를 포함하는 탈모방지 및 발모 촉진용 조성물